Residency · Residency · Radiation Oncology
Prostate Cancer: Low-Risk Disease and Active Surveillance vs. Definitive Treatment
Introduction
Low-risk prostate cancer presents a clinical scenario where it is essential to carefully weigh the benefits of treatment against potential harms. According to the National Comprehensive Cancer Network (NCCN), low-risk disease is defined by a Gleason score of 6 (Grade Group 1), a prostate-specific antigen (PSA) level below 10 ng/mL, and a clinical stage of T1c to T2a. Patients with low-risk prostate cancer generally have excellent outcomes regardless of whether they undergo active surveillance or definitive treatment. Therefore, understanding when to observe the disease versus when to intervene with treatment is a fundamental aspect of contemporary urologic and radiation oncology practice.
Risk Stratification
NCCN Risk Groups
The NCCN categorizes prostate cancer into several risk groups to guide management. Very low-risk disease is characterized by clinical stage T1c, Gleason score 6, PSA less than 10 ng/mL, fewer than three positive biopsy cores with each core having less than 50% tumor involvement, and a PSA density below 0.15. Low-risk disease includes clinical stages T1 to T2a, Gleason 6, and PSA under 10 ng/mL but does not meet the very low-risk criteria. Favorable intermediate-risk disease is defined by clinical stages T2b to T2c or a Gleason score of 3+4=7 or PSA levels between 10 and 20 ng/mL, with only one intermediate-risk factor present, less than 50% positive biopsy cores, and Gleason Grade Group 1 or 2.
| NCCN Risk Group | Clinical Stage | Gleason / Grade Group | PSA | Additional Criteria |
|---|---|---|---|---|
| Very low risk | T1c | 6 (GG1) | < 10 ng/mL | < 3 cores positive, < 50% per core, PSA density < 0.15 |
| Low risk | T1–T2a | 6 (GG1) | < 10 ng/mL | Does not meet very low-risk criteria |
| Favorable intermediate | T2b–T2c | 3+4 (GG2) | 10–20 ng/mL | 1 intermediate-risk factor, < 50% cores positive |
| Unfavorable intermediate | T2b–T2c | 4+3 (GG3) | 10–20 ng/mL | ≥ 2 intermediate-risk factors or GG3 |
Genomic Classifiers
Beyond traditional clinicopathologic features, genomic classifiers such as Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris provide additional risk refinement. These tools help identify patients within the low-risk category who may harbor more aggressive tumor biology that is not apparent from standard clinical parameters. Increasingly, genomic testing is integrated into shared decision-making processes to determine candidacy for active surveillance, allowing for more personalized management strategies.
Active Surveillance
Rationale
The rationale for active surveillance is supported by evidence from the ProtecT trial, which demonstrated no significant difference in prostate cancer-specific mortality at 15 years among patients treated with surgery, radiation, or active monitoring for localized prostate cancer. Active surveillance aims to avoid the side effects associated with definitive treatments, such as erectile dysfunction, urinary incontinence, and bowel toxicity. However, it is important to note that approximately 30-40% of men on active surveillance will eventually require delayed treatment within 10 years due to disease progression or other factors.
Surveillance Protocols
Active surveillance protocols typically involve monitoring PSA levels every three to six months and performing digital rectal examinations annually. A confirmatory biopsy is generally recommended within six to twelve months of diagnosis, followed by repeat biopsies every two to four years. Multiparametric MRI (mpMRI) has become an increasingly valuable tool in guiding surveillance by helping to identify areas of concern and target biopsies more accurately.
Triggers for Intervention
Intervention during active surveillance is usually prompted by grade reclassification to Gleason 7 or higher on repeat biopsy, an increase in tumor volume or the number of positive biopsy cores, or patient preference after thorough counseling about risks and benefits.
Definitive Treatment Options
External Beam Radiation Therapy (EBRT)
External beam radiation therapy for low-risk prostate cancer can be delivered using conventional fractionation, typically 75.6 to 79.2 Gy in 1.8 Gy fractions. Moderate hypofractionation, which involves delivering 60 Gy in 20 fractions or 70 Gy in 28 fractions, is now preferred due to convenience and comparable outcomes. Stereotactic body radiation therapy (SBRT) or ultra-hypofractionation, delivering 36.25 Gy in 5 fractions, is another option discussed in more detail in Lecture 44. Importantly, androgen deprivation therapy (ADT) is not indicated for low-risk disease when radiation is used.
Low-Dose Rate (LDR) Brachytherapy
LDR brachytherapy involves permanent seed implantation using isotopes such as I-125 or Pd-103. The typical prescription dose for monotherapy is 145 Gy for I-125 or 125 Gy for Pd-103. This treatment is an excellent option for patients with favorable anatomy, including a prostate volume less than 60 cc, no history of transurethral resection of the prostate (TURP), and a low International Prostate Symptom Score (IPSS).
Radical Prostatectomy
Radical prostatectomy can be performed via open, laparoscopic, or robot-assisted approaches and provides valuable pathologic staging information. Compared with radiation therapy, surgery is associated with higher rates of urinary incontinence, which can persist in 10-15% of patients, while rates of erectile dysfunction are comparable between the two modalities.
Outcomes Comparison
Cancer Control
All definitive treatment modalities for low-risk prostate cancer achieve excellent cancer control, with 10-year biochemical recurrence-free survival rates exceeding 90-95%. Prostate cancer-specific mortality at 15 years remains below 5% regardless of the treatment approach. The ProtecT trial further confirmed equivalent cancer-specific survival among patients undergoing monitoring, surgery, or radiation at 15 years.
Quality of Life
Quality of life outcomes differ by treatment modality. Surgery is associated with higher rates of early urinary incontinence, which may persist in a subset of patients, and erectile dysfunction is common. Radiation therapy tends to cause a gradual onset of bowel and urinary symptoms, with erectile dysfunction developing over two to five years. Active surveillance preserves baseline urinary and sexual function but may be accompanied by anxiety related to living with untreated cancer.
Shared Decision-Making
Shared decision-making is critical in managing low-risk prostate cancer and should incorporate patient age, comorbidities, and life expectancy. Men with a life expectancy of less than 10 years generally derive minimal benefit from definitive treatment. Patient values and preferences regarding side effect profiles should guide management choices. Ideally, a multidisciplinary evaluation involving urology, radiation oncology, and primary care providers supports optimal decision-making.
Key Clinical Pearls
Active surveillance is the preferred management strategy for very low-risk and most low-risk prostate cancer cases according to NCCN guidelines. The ProtecT trial demonstrated no difference in prostate cancer-specific mortality at 15 years among monitoring, surgery, and radiation for localized disease. Genomic classifiers such as Decipher, Oncotype DX GPS, and Prolaris provide valuable risk refinement and support decisions regarding active surveillance. When definitive treatment is selected for low-risk disease, androgen deprivation therapy is not indicated, and outcomes are equivalent across treatment modalities. Multiparametric MRI has become an essential tool for both initial diagnosis and ongoing monitoring during active surveillance.
References
- Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558.
- Tosoian JJ, Mamawala M, Epstein JI, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. 2020;77(6):675-682.
- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2025.
- Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272-277.